Loading...

IVVD INVIVYD INC Expansion Plans 8-K Filing

NVVY

VVD

INVIVYD INC

(IVVD)

2026 8-K

Measles Treatment Update

Financial Update

Q4 2025 Revenue

Fast Track Designation

Public Offering Details

Quarterly Results

Investor Presentation

FDA Clearance Announcement

Board Appointment

Public Offering Announcement

FDA Approval Pathway

SPEAR Study Group

Product Expansion

Financial Statements

Product Expansion

Failure to Meet Listing Sta...

Director Appointment

Financial Results

Nasdaq Compliance

Q4 2024 Results

PEMGARDA Update

Director Resignation

Financial Results

Q3 2024 Results

Virology Data Release

Corporate Update

Clinical Trial Launch

PEMGARDA Update

COVID-19 Treatment Update

Financial Results

Management Changes

Annual Meeting of Stockholders

Financial Results and Corpo...

Departure of CEO and Appoin...

Financial Results Announcement

Departure of Director, Refi...

Other Special Situation

Sales Agreement

Clinical Trial Results

Financial Results Announcement

Earnings Report

Appointment of Director

Amendment to Certificate of...

Financial Results Announcement

Incentive Program Approval

Financial Results Announcement

Announcement of COVID-19 th...

External Links:

Invivyd, Inc. announced progress on its REVOLUTION Program, highlighting its monoclonal antibody candidate VMS063 for measles treatment and prevention on April 9, 2026.

AI Assistant

INVIVYD INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.